Results 201 to 210 of about 92,043 (285)

Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report. [PDF]

SAGE Open Med Case Rep
Te B, Roesler J, Kunimoto B.
europepmc   +1 more source

Spondyloarthritis Associated With Collagenous Colitis—Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Collagenous colitis (CC) is a subtype of microscopic colitis characterized by chronic watery diarrhea with normal endoscopic findings. Although often linked to autoimmune diseases, its association with spondyloarthropathy (SpA) is rare and poorly documented.
Charlotte Bouvy, Abeline Kapuczinski, Sophiane Ibrahimi, Marc Léon, Nathalie Demeulenaere   +4 more
wiley   +1 more source

Morphea Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Morphea is a localized autoimmune fibrosing disorder that may paradoxically develop during anti‐TNFα agents in ankylosing spondylitis (AS). We report a second case of morphea associated with long‐term golimumab use in a patient with AS, presenting with indurated plaques and confirmed histopathologically.
Faten Hilwanjee, Yumn Alghabra, Raghad Aldalati, Nada Al Chama   +3 more
wiley   +1 more source

Adalimumab in the management of refractory idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome: a case report and literature review. [PDF]

BMC Ophthalmol
Qadan AB, Zafar MI, Tanveer MA, Berstad BB, Jansson RW.   +4 more
europepmc   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

Melkersson-Rosenthal Syndrome: A Case Treated With Infliximab. [PDF]

Cureus
Correia FA, Costa A, Pinto C, Chaves V, Almeida J.   +4 more
europepmc   +1 more source

A Case of Fulminant Immune‐Related Enterocolitis During Immune Checkpoint Inhibitor Therapy for Metastatic Renal Cell Carcinoma

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction Combination therapy with immune checkpoint inhibitors (ICIs) has become a standard treatment for metastatic renal cell carcinoma (mRCC). However, ICIs may also cause immune‐related adverse events. We report a case of mRCC that developed fulminant immune‐related enterocolitis.
Kasumi Kanai, Takayuki Sumiyoshi, Hiroki Kitamoto, Yuki Teramoto, Yuta Mine, Jin Kono, Kimihiko Masui, Takayuki Goto, Ryoichi Saito, Takashi Kobayashi   +9 more
wiley   +1 more source

Do we need to treat dialysis patients differently? Infliximab therapy in a patient with ulcerative colitis on hemodialysis: a case report. [PDF]

J Med Case Rep
Balogh F, Angyal D, Gonczi L, Lontai L, Lakatos PL, Ilias A.   +5 more
europepmc   +1 more source

Growth in Paediatric Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 3, May 2026.
ABSTRACT Impaired linear growth is a common, clinically meaningful complication of paediatric inflammatory bowel disease (IBD), particularly Crohn's disease, arising from the combination of chronic intestinal inflammation, undernutrition, dysfunction of the growth hormone–insulin‐like growth factor‐1 axis, and iatrogenic effects such as glucocorticoid ...
Firas Rinawi, Séamus Hussey, Eileen Crowley, Dror S. Shouval, Iva Hojsak   +4 more
wiley   +1 more source